Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) shares were down 10% on Wednesday . The company traded as low as $14.44 and last traded at $14.44. Approximately 732 shares traded hands during trading, a decline of 100% from the average daily volume of 175,207 shares. The stock had previously closed at $16.04.
Wall Street Analyst Weigh In
SION has been the subject of a number of recent research reports. Wall Street Zen cut shares of Sionna Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Stifel Nicolaus began coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating and a $32.00 price target for the company. TD Cowen began coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They set a "buy" rating on the stock. Finally, Guggenheim began coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They set a "buy" rating and a $45.00 price objective on the stock.
Check Out Our Latest Stock Report on Sionna Therapeutics
Sionna Therapeutics Stock Performance
The business's fifty day moving average price is $13.94.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.17).
Institutional Trading of Sionna Therapeutics
Large investors have recently made changes to their positions in the business. Zimmer Partners LP acquired a new position in Sionna Therapeutics during the 1st quarter worth about $2,484,000. Alyeska Investment Group L.P. acquired a new position in Sionna Therapeutics during the 1st quarter worth about $1,948,000. Charles Schwab Investment Management Inc. acquired a new position in Sionna Therapeutics during the 1st quarter worth about $676,000. RA Capital Management L.P. acquired a new position in Sionna Therapeutics during the 1st quarter worth about $109,258,000. Finally, Baker BROS. Advisors LP acquired a new position in Sionna Therapeutics during the 1st quarter worth about $4,184,000.
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Stories
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
